Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:21:05.234Z.
Calculation as of: 2026-10-06T16:21:05.234Z.
Quote observation: 2026-10-06T16:20:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fdfad12185ff1a6c55ef1236bc2340ccae7aa6e4dec3824b1e7761c8ffaeec30
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alvotech (ALVO) | $2.06B | N/A | N/A | N/A | N/A |
| Fortrea Holdings Inc. (FTRE)vs › | $2.07B | N/A | N/A | N/A | N/A |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.05B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.09B | N/A | N/A | N/A | N/A |
| Progyny, Inc. (PGNY)vs › | $2.04B | 4.23 | 4.69 | 1.94 | 1.94 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | N/A | N/A | N/A | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 0.98 | 1.08 | 1.19 | 1.40 |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.00B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.99B | N/A | N/A | N/A | N/A |
| Pharvaris N.V. (PHVS)vs › | $2.14B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
